全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Peginterfer o α2-a na co-infec o VHB --- VH delta: Um caso de duplo sucesso terapêutico Peginterferon_2-a in HBV HVD coinfection: A case of double therapeutic success

Keywords: Co-infec o , VHB , VHD , Peginterfer o , Coinfection , HBV , HDV , Peginterferon

Full-Text   Cite this paper   Add to My Lib

Abstract:

O vírus da hepatite D (VHD) é um vírus satélite, que necessita do vírus da hepatite B (VHB) para a sua replica o. Na maioria dos casos, o VHD suprime a replicac o do VHB e, nestas circunstancias, está recomendado o tratamento com Interfer o. Nos doentes em que n o se observa resposta virológica após o 1. ano de terapêutica, o seu prolongamento pode aumentar a taxa de resposta virológica sustentada. Caso clínico: Homem, 42 anos, com hepatite crónica B, anti-HBe positivo e baixa carga viral. Apresentava aminotransferases aumentadas que persistiram, mesmo após negativa o do ADNVHB. A positividade da fra o IgM do AcVHD conduziu ao diagnóstico de co-infec o VHB-VHD. Foi tratado com PegInterfe o _-2a durante 102 semanas. Observou-se normaliza o das aminotransferases à 33.a semana, negativa o da IgM do AcVHD à 88.a semana e resposta virológica sustentada com perda do AgHB. Comentários: Este caso ilustra a importancia de se manter o tratamento nos doentes com infec o VHD até resposta virológica, uma vez que a cura do VHD pode acompanhar-se da cura da infec o VHB. Hepatitis D virus (HDV) is a satellite virus which needs hepatitis B virus (HBV) for its replication. In most cases, HDV suppresses HBV replication and in these circumstances the treatment should be with Interferon. In patients that have no virological response after the 1th year of therapy, continuing it will possible increase the virological response and the loss of the HBs antigen. Case report: 42 years old man with chronic HBV, anti-HBe positive and low HBV viral load. He had increased transaminases which had persisted even after HBV-DNA negativation. We performed antibody anti-HDV that came positive and treated the patient with PegInterferon α-2a during 102 weeks. We assist to normalization of the transaminases at week 33 and negativation of IgM-HVD at week 88. At the end of the treatment RNA-HDV was negative and the patient lost HBs antigen that persisted over the next sixth months. Comments: This case illustrates the importance of maintaining treatment until HDV virological response since the cure of the HDV may be accompanied by the cure of HBV infection.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133